DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

导出原文传递

翻译打印收藏纠错

作者： Ogitani, Yusuke ^[1] ; Aida, Tetsuo ^[2] ; Hagihara, Katsunobu ; Yamaguchi, Junko ; Ishii, Chiaki ; Harada, Naoya ; Soma, Masako ; Okamoto, Hiromi ; Oitate, Masataka ; Arakawa, Shingo ; Hirai, Takehiro ; Atsumi, Ryo ; Nakada, Takashi ; Hayakawa, Ichiro ; Abe, Yuki ; Agatsuma, Toshinori

作者单位： Daiichi Sankyo RD Novare Co Ltd, Clin Dev Dept, Tokyo, Japan ^[1] Daiichi Sankyo Co Ltd, Tokyo, Japan ^[2]

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览3

Clinical cancer research

2016年22卷20期

5097-5108页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除